Tests several new medicines for long-term weight control in adults with obesity
Tests several investigational medicines for weight control in adults with obesity or overweight.
Plain-language title generated from the registry record
Registry title: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Key facts
- Where
- Buenos Aires and Rosario, ArgentinaSee the 7 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity or overweight whose body weight has been stable for the last 3 months. It tests several study treatments for long-term weight management.
- Age
- 18 Years to 75 Years
- Sex
- All sexes can join.
- Disease stage
- Body mass index (BMI) of at least 30 kg/m², or BMI of at least 27 kg/m² and less than 30 kg/m² with at least 1 weight-related health problem.
- Earlier treatment
- Stable body weight for the 3 months before randomization (less than 5% weight gain or loss). No prior or planned weight-loss surgery, except liposuction or abdominoplasty done more than 1 year before screening.
Main reasons for not taking part
- Type 1 diabetes, latent autoimmune diabetes in adults, or a history of ketoacidosis or hyperosmolar coma
- Poorly controlled high blood pressure
- Liver disease other than nonalcoholic fatty liver disease
- Heart attack, stroke, unstable angina or hospital stay for heart failure in the 3 months before screening
- Symptomatic gallbladder disease in the past 2 years, or any suicide attempt in life
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06143956, who can take part
Where in Argentina
- CARDIAMET Investigaciones MédicasBuenos Aires, ArgentinaContact: Angela Romero Zarante (principal investigator)Not yet recruiting
- Centro de Investigaciones Metabólicas (CINME)Buenos Aires, ArgentinaContact: Federico Perez Manghi (principal investigator)Taking people
- Centro Medico Dra. Laura Maffei- Investigacion Clinica AplicadaBuenos Aires, ArgentinaContact: Evelyn Blanc (principal investigator)Taking people
- Centro Médico ViamonteBuenos Aires, ArgentinaContact: Diego Aizenberg (principal investigator)Taking people
- Cicemo SrlBuenos Aires, ArgentinaContact: Pablo Costanzo (principal investigator)Taking people
- Mautalen Salud e InvestigaciónBuenos Aires, ArgentinaContact: Jose Fretes (principal investigator)Not yet recruiting
- Instituto Médico Catamarca IMECRosario, ArgentinaContact: Natacha Maldonado (principal investigator)Not yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT06143956
- Record updated
- 7 October 2026
- Original description
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record will be reported when all the ISA's complete.Read full original descriptionShow less
A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Interventions for Chronic Weight Management in Adult Participants With Obesity or Overweight
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record will be reported when all the ISA's complete.
Inclusion: Have a body mass index (BMI); ≥30 kilogram/square meter (kg/m²), or; ≥27 kg/m² and <30 kg/m², or with at least 1 weight-related comorbidity; Have had a stable body weight for the 3 months prior to randomization (<5%) body weight gain and/or loss.
Exclusion: Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening; Have any of the following cardiovascular conditions within 3 months prior to screening:; acute myocardial infarction; cerebrovascular accident (stroke); unstable angina, or; hospitalization due to congestive heart failure; Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma; Have poorly controlled hypertension; Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease; Have a history of symptomatic gallbladder disease within the past 2 years; Have a lifetime history of suicide attempts.